Loading stock data…
Rapport Therapeutics (RAPP)
$40.39+0.33 (+0.82%)
After Hours$40.39+0.00 (+0.00%)· Last close Jun 29
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rapport Therapeutics, Inc. in the Healthcare sector is trading at $40.39 with a market capitalization of $1.8B. Wall Street consensus targets $56.64 (11 analysts), implying a +40.2% move over the next 12 months. The stock is currently near its 52-week high of $42.27, remaining 32.6% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +40.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20.00M | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$24.21M↑ | -$38.51M↓ | -$29.99M↓ | -$29.50M↓ | -$27.11M |
| Net Income | -$19.86M↑ | -$33.76M↓ | -$26.93M↓ | -$26.73M↓ | -$24.06M |
Peer Comparison
JNJUNHPFE
Fundamentals
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The comp...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.78B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.75%
Volume
Today's trading volume
424,351
Recent News
Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?
Is RAPP a good stock to buy? We came across a bullish thesis on Rapport Therapeutics, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on RAPP. Rapport Therapeutics, Inc.’s share was trading at $38.26 as of June 15th. RAPP’s trailing P/E was 23.78 according to Yahoo Finance. Rapport Therapeutics (RAPP) is a […]
Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?
In late May 2026, analysts BTIG and Truist highlighted Rapport Therapeutics’ RAP-219 program after the company reported progress toward Phase 3 trials, supported by earlier Phase 2a follow-up data. An interesting angle is how RAP-219’s dual focus on epilepsy and bipolar mania, including a planned long-acting injectable, could broaden Rapport’s clinical opportunity set. We’ll now examine how this momentum in RAP-219, particularly its Phase 3 preparation, influences Rapport Therapeutics’...
BTIG Raises its Price Target on Rapport Therapeutics (RAPP)
Rapport Therapeutics, Inc. (NASDAQ:RAPP) is one of the 10 Stocks That Have the Potential to Rise 1000%. On May 21, 2026, BTIG raised the firm’s price target on Rapport Therapeutics, Inc. (NASDAQ:RAPP) to $65 from $53 and maintained a Buy rating on the shares. BTIG cited clinical execution behind its more constructive stance on RAP-219 […]
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
Rapport Therapeutics, Inc. (RAPP) delivered earnings and revenue surprises of +24.66% and 0.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings
Over the last year, a good number of insiders have significantly increased their holdings in Rapport Therapeutics, Inc...